"Cancer"

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

Blood cancer is a very complicated disease and should be treated in a timely manner to improve your disease and health condition and to gradually relieve your symptoms.

The US FDA approved the ADC drug gosatumumab (Trodelvy) for the treatment of patients with hormone receptor-positive, HER2-negative breast cancer. In the trial, the drug significantly extended the overall survival of patients and reduced the risk of death by 21%.

The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).

Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.

The University of Washington Medical Center owns and manages CUMG and the Seattle Cancer Care Alliance, which is a joint venture between the University of Washington Medical Center, Fred Hutchinson Cancer Research Center and Seattle Children's Hospital.

Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.

Nectin-4 is an important target that has been shown to be available as a treatment for locally advanced and advanced bladder cancer. Based on this, Padcev (enfortumab-vedotin-ejfv), the first ADC drug (antibody-coupled drug) for uroepithelial carcinoma, has also received accelerated FDA approval for the treatment of locally advanced or advanced bladder cancer in patients who have previously received immune checkpoint inhibitors (PD-L1, PD-1) and platinum-containing chemotherapy before surgery (neoadjuvant therapy) or after surgery (adjuvant therapy). Adult patients with advanced or late-stage uroepithelial carcinoma (a common type of bladder cancer).

The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.

Stomach cancer can cause abnormal symptoms in the digestive system, even vomiting blood and black stools, so it should be treated promptly after having stomach cancer